Ultrasound-Guided Needle Aspiration Biopsy of Superficial Metastasis of Lung Cancer with and without Rapid On-Site Evaluation: A Randomized Trial.
bronchoscopy and interventional techniques
lung cancer
pathology
radiology and other imaging
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Oct 2022
21 Oct 2022
Historique:
received:
19
08
2022
revised:
12
10
2022
accepted:
17
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Studies which evaluated the role of an ultrasound-guided needle aspiration biopsy (US-NAB) of metastases from lung cancer located in "superficial" organs/tissues are scant, and none of them assessed the possible impact of rapid on-site evaluation (ROSE) on diagnostic accuracy and safety outcomes. Consecutive patients with suspected superficial metastases from lung cancer were randomized 1:1 to US-NAB without (US-NAB group) or with ROSE (ROSE group). The diagnostic yield for a tissue diagnosis was the primary outcome. Secondary outcomes included the diagnostic yield for cancer genotyping, the diagnostic yield for PD-L1 testing, and safety. During the study period, 136 patients were randomized to receive an US-NAB with ( US-NAB of superficial metastases is safe and has an excellent diagnostic success regardless of the availability of ROSE. These findings provide a strong rationale for using US-NAB as the first-step method for tissue acquisition whenever a suspected superficial metastatic lesion is identified in patients with suspected lung cancer.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Studies which evaluated the role of an ultrasound-guided needle aspiration biopsy (US-NAB) of metastases from lung cancer located in "superficial" organs/tissues are scant, and none of them assessed the possible impact of rapid on-site evaluation (ROSE) on diagnostic accuracy and safety outcomes.
METHODS
METHODS
Consecutive patients with suspected superficial metastases from lung cancer were randomized 1:1 to US-NAB without (US-NAB group) or with ROSE (ROSE group). The diagnostic yield for a tissue diagnosis was the primary outcome. Secondary outcomes included the diagnostic yield for cancer genotyping, the diagnostic yield for PD-L1 testing, and safety.
RESULTS
RESULTS
During the study period, 136 patients were randomized to receive an US-NAB with (
CONCLUSION
CONCLUSIONS
US-NAB of superficial metastases is safe and has an excellent diagnostic success regardless of the availability of ROSE. These findings provide a strong rationale for using US-NAB as the first-step method for tissue acquisition whenever a suspected superficial metastatic lesion is identified in patients with suspected lung cancer.
Identifiants
pubmed: 36291940
pii: cancers14205156
doi: 10.3390/cancers14205156
pmc: PMC9600579
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Crit Rev Oncol Hematol. 2020 Feb;146:102858
pubmed: 31918343
Lung Cancer. 2021 Nov;161:152-162
pubmed: 34600406
Respiration. 2019;97(6):540-547
pubmed: 30982053
Am J Respir Crit Care Med. 2002 Aug 1;166(3):377-81
pubmed: 12153974
J Thorac Oncol. 2018 Sep;13(9):1248-1268
pubmed: 29885479
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Am J Respir Crit Care Med. 2016 Jan 1;193(1):68-77
pubmed: 26367186
J Thorac Oncol. 2019 Mar;14(3):445-458
pubmed: 30476574
JTO Clin Res Rep. 2022 May 07;3(6):100336
pubmed: 35677681
ERJ Open Res. 2020 Feb 10;6(1):
pubmed: 32055635
J Thorac Oncol. 2020 Sep;15(9):1399-1400
pubmed: 32854912
Respiration. 2012;83(1):45-52
pubmed: 21934274
Chest. 2013 May;143(5 Suppl):e142S-e165S
pubmed: 23649436
Lung Cancer. 2022 May;167:41-48
pubmed: 35397297
Am J Gastroenterol. 2018 May;113(5):677-685
pubmed: 29681624
AJR Am J Roentgenol. 2015 Jan;204(1):29-34
pubmed: 25539234
Chest. 2015 Dec;148(6):1430-1437
pubmed: 26158441
Ann Diagn Pathol. 2013 Aug;17(4):322-6
pubmed: 23660273
Chest. 2011 Feb;139(2):395-401
pubmed: 21030491
Chest. 1990 Jul;98(1):59-61
pubmed: 2361413
J Bronchology Interv Pulmonol. 2011 Apr;18(2):121-7
pubmed: 23169079
Respir Res. 2013 May 10;14:50
pubmed: 23663438
Respir Care. 2015 Jul;60(7):1040-50
pubmed: 25759463
Radiology. 2022 Feb;302(2):473-480
pubmed: 34726537
J Thorac Oncol. 2020 Sep;15(9):1434-1448
pubmed: 32445813
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Respiration. 2004 Sep-Oct;71(5):519-22
pubmed: 15467331
Eur Radiol. 2017 Jan;27(1):138-148
pubmed: 27108299
Respiration. 2014;87(6):441-51
pubmed: 24853327
Chest. 2000 Apr;117(4):1186-90
pubmed: 10767258
Respiration. 2012;84(4):337-50
pubmed: 22832423
J Bronchology Interv Pulmonol. 2016 Jul;23(3):220-8
pubmed: 27454475
N Engl J Med. 2022 May 26;386(21):1973-1985
pubmed: 35403841
Surg Oncol Clin N Am. 2020 Jan;29(1):15-21
pubmed: 31757310
Respiration. 2021;100(6):515-522
pubmed: 33827098
Cytopathology. 2020 Jul;31(4):303-309
pubmed: 32463969
Respiration. 2013;85(6):486-92
pubmed: 23571718